Abstract
Background: Acute lymphoblastic leukemia (ALL) is biologically and clinically considered as a heterogeneous neoplasm of lymphoid progenitor cells. About 85% of children with ALL are diagnosed as B-ALL, expressing CD19; the typical marker of normal B cells. Problem: Given that the chemotherapy associated with leucopenia, in particular myeloid cells (CD33+ cells), Aim: the main aim of this study was to analyze the numbers of these cells in children with B-ALL before and after induction of chemotherapy. Materials and Methods: The frequencies of CD33+ myeloid cells and CD19+ B-cells were analyzed in the peripheral blood patients before (n = 10) and after (n = 10) induction of chemotherapy as well as in healthy volunteers (n = 10) using multiparametric flow cytometry. Results: As expected, B-ALL patients showed high numbers of CD19+ cells before induction of chemotherapy; where the numbers of these cells were reduced upon the induction of chemotherapy. CD33+ myeloid cells showed decrease in numbers in B-ALL patients before chemotherapy as compared to healthy control volunteers. Interestingly, treatment of B-ALL patients with chemotherapy-induced almost recovery of the numbers of these cells. Conclusion: CD33+ myeloid cells are increased in numbers after induction of chemotherapy, indicating to a dynamic mobilization or differentiation of their precursors into circulation. This study opens a new avenue to characterize the phenotype and function of these cells in different hematological malignancies; in particular, they may harbor regulatory cells.
Cite
CITATION STYLE
Salem, M., El-Shanshory, M., El-Naggar, R. E.-D., Abdou, S., Attia, M., Zidan, A.-A., & Zidan, M. (2015). Reduction in the numbers of CD33 + myeloid population in Egyptian children with B-linage acute lymphoblastic leukemia and its recovery after induction of chemotherapy. Clinical Cancer Investigation Journal, 4(5), 627. https://doi.org/10.4103/2278-0513.164716
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.